✦ LIBER ✦

469 Incidence of selected adverse events (AEs) in phase III studies of bevacizumab (BV) in combination with chemotherapy for the treatment of HER2-negative metastatic breast cancer (mBC)

✍ Scribed by D.W. Miles; V. Dieras; J. Glaspy; A. Brufsky; P. Koralewski; S.C. Phan; N.J. Robert

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

489 Bevacizumab (BV) in combination with

✍ J. Glaspy; V. Dieras; A. Brufsky; D.W. Miles; S.C. Phan; J. O'Shaughnessy 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

476 PFS by patient subgroup for standard

✍ I. Bondarenko; J. Glaspy; A. Brufsky; O. Lipatov; E.A. Perez; S. Chan; X. Zou; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

1423 POSTER Polymorphism Analysis in the

✍ D.W. Miles; S.L. De Haas; G. Romieu; A. Chan; L. Dirix; J. Cortes; P.R. Delmar; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

455 A phase II study of first-line combi

✍ F. Lenz; F. Beldermann; M. Geberth; G. Bastert; A. Schneeweiss 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

480 Evidence from the phase III AVADO st

✍ A. Chan; D.W. Miles; D. ten Bokkel Huinink; X. Durando; C. Fabiani; S. Salvagni; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 65 KB

5016 Efficacy in patient subgroups in RI

✍ V. Dieras; J. Glaspy; A. Brufsky; I. Bondarenko; O. Lipatov; E.A. Perez; S. Chan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB